Email this article Indices of endothelial function in patients with cancer of the digestive tract
- Authors: Olzhayev S.T.1, Lazarev A.F2, Shoykhet Y.N3
-
Affiliations:
- Almaty Regional Oncology Center
- N.N. Blokhin Russian Cancer Research Center
- Altai State Medical University
- Issue: Vol 21, No 6 (2016)
- Pages: 300-302
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40302
- DOI: https://doi.org/10.18821/1028-9984-2016-21-6-300-302
- ID: 40302
Cite item
Full Text
Abstract
The aim of the study was the determination of the degree of the pronouncement of the endothelial dysfunction in patients with stomach, pancreatic and liver cancer. Results of clinical-laboratory and instrumental observation of 295 patients with stomach, pancreatic and liver cancer were analysed. The study included 122 patients with stomach cancer, including 87 (71.3%) men and 35 (28.7%) women, aged of 62.2 ± 2.3 years. Pancreatic cancer (95 cases) was found in 52 (54.7%) men and 43 (45.3%) women, aged of 61.7 ± 2.1 years. Patients with liver cancer were presented by 57 (73.1%) men and 21 (26.9%) women, aged of 62.2 ± 3.0 years. The following methods were used: determination of the content of the desquamed endotheliocytes in blood according to Hladovec J. et al.; the maintenance of a von Willebrandfactor (VWF) in serum; Doppler echocardiography test with a reactive hyperemic response of the brachial artery. There was noted the significant increase both of the maintenance of the circulating endotheliocytes and VWF and the decrease in endothelium-dependent vasodilatation in all groups of patients with malignancy. The most considerable changes were revealed in the group ofpatients with a liver cancer. Malfunction of endothelium was associated with the pathological activation of vascular-platelet link of hemostasis system.
Full Text
##article.viewOnOriginalSite##About the authors
Sayakhat T. Olzhayev
Almaty Regional Oncology Center
Email: s.olzhayev20@gmail.com
MD, PhD, Head of the Almaty Regional Oncology Center Almaty, 050019, Republic of Kazakhstan
A. F Lazarev
N.N. Blokhin Russian Cancer Research CenterAltaysky branch Barnaul, 656049, Russian Federation
Ya. N Shoykhet
Altai State Medical UniversityBarnaul, 656038, Russian Federation
References
- Rajendran P., Rengarajan T., Thangavel J., Nishigaki Y., Sakthisekaran D., Sethi G., Nishigaki I. The vascular endothelium and human disease. Int. J. Biol. Sci. 2013; 9(10): 1057-69.
- Radenković M., Stojanović M., Potpara T., Prostran M. Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art. Biomed Res. Int. 2013; 2013/ 252158.
- Щербаков А.М., Герштейн Е.С., Кушлинский Н.Е., Анурова О.А. Фактор роста эндотелия сосудов и его рецепторы первого и второго типа при раке молочной железы. Вопросы онкологии. 2005; (3): 317-21.
- Li M., Yang H., Chai H., Fisher W.E., Wang X., Brunicardi F.C., Yao Q., Chen C. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer. 2009; 101(10): 2341-50.
- Madoiwa S. Cancer and thrombosis. Gan To Kagaku Ryoho. 2011; 36(11): 1781-7.
- Dinh Q.N., Drummond G.R., Sobey C.G., Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed. Res. Int. 2014; 2014. 406960.
- Ichihara E., Kiura K., Tanimoto M. Targeting angiogenesis in cancer therapy. Acta Med. Okayama. 2011; 65(6): 353-62.
- Keefe D., Bowen J., Gibson R., Tan T., Okera M., Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011; 16(4): 432-44.
- Maida M., Orlando E., Cammà C., Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J. Gastroenterol. 2014; 20(15): 4141-50.
Supplementary files
